Opus Genetics, Inc. (IRD)

Opus Genetics, Inc. (IRD) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $318M; returns 1 day -9.2%, 1 week -9.6%, 1 year +73.5%.

Opus Genetics, Inc. (IRD) is a clinical-stage biopharmaceutical company focused on developing gene therapies to restore vision and prevent blindness in patients suffering from inherited retinal diseases (IRDs). The company's primary revenue is generated through license and collaboration agreements, including a significant partnership with Viatris, Inc.

Groups IRD belongs to

• Biotechnology
• Clinical Stage Biotech
• Gene Therapy
• Ophthalmology
• Healthcare
• Biopharmaceutical
• Clinical Stage
• Pharmaceuticals
• Life Sciences
• Rare Diseases
• R&D

IRD financial model: income statement, cash flow and balance sheet